RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate CancerHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 18 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate CancerPR NewswireJanuary 10, 2020ReblogShareTweetShareSTOCKHOLM, Jan. 10, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 10th January 2020, that the company has received approval from Beligian FAMHP (Federal Agency for Medicines and Health Products) and German Federal Institute for Vaccines and Biomedicines for starting the clinical phase IIb study in prostate cancer, a multicenter study entitled RhoVac-002 ("BRaVac"). The phase IIb study is an international, multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States. RhoVac has previously received approval Denmark and Finland.BRaVac is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating if and to what extent treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent therapy measured as a limited development of PSA (Prostate Specific Antigen) in actively treated patients compared to the control group (placebo group). The Phase IIb study is an international multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States. The ambition is for all patients to be recruited by end Q3 2020. The results reporting on the primary objective of the study is expected during H2 2021. RhoVac has previously received CTA approval in Denmark and Finland.For further information, please contact: Anders Månsson – CEO, RhoVac ABPhone number: +46-73-751-72-78E-mail: info@rhovac.comThis information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 29th October 2019.This information was brought to you by Cision http://news.cision.comhttps://news.cision.com/rhovac/r/rhovac-receives-approval-in-germany-and-belgium-to-start-clinical-phase-iib-study-in-prostate-cancer,c3006176The following files are available for download: https://mb.cision.com/Main/13747/3006176/1172548.pdf
Release
CisionMoreView original content:http://www.prnewswire.com/news-releases/rhovac-receives-approval-in-germany-and-belgium-to-start-clinical-phase-iib-study-in-prostate-cancer-300984869.htmlSOURCE RhoVacReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoKorea Cases Top 2,000; Nigeria Confirms Infection: Virus UpdateBloombergWhat the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoWoman Who Snorted 550 Times the Usual Dose of LSD Survives and Experiences Dramatic Pain ReliefPeopleLoan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceU.S. airlines suspend flights over coronavirus fearsYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance